Kenya is Among three African Countries that are set to participate in a medical trial by IAVI- a global research organisation- and Biofabri that aims to evaluate the efficacy level of the MTBVAC vaccine in the prevention of TB disease in adolescents and adults with latent TB infection.
In a statement, IAVI said that the trial-IMAGINE(Investigation of MTBVAC toward Accelerating Global Immunization for a Neglected Epidemic) phase 2b Clinical trial which will involve 4,300 participants with latent TB infection, will be conducted across 15 sites in South Africa, Kenya and Tanzania.
In Kenya, the study will be conducted at the Kenya Medical Research Institute/Center for Respiratory Disease Research in Nairobi and the Victoria Biomedical Research Institute in Kisumu. "MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial, a large-scale safety and efficacy trial evaluating the prevention of TB disease in adolescents and adults with latent TB infection in South Africa, Kenya, and Tanzania," the statement read.
An image of the polio vaccine.
